Phospholipids as cardiovascular therapeutics

Current Opinion in Investigational Drugs

Volumn 9, Issue 3, 2008, Pages 281-285

  Pandey, N R ^a   Sparks, D L ^a,b  

^a Liponex Inc   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Apolipoprotein A I; Dyslipidemia; HDL cholesterol; Linoleic acid; Peroxisome proliferator activated receptor ; Phospholipid

Indexed keywords

APOLIPOPROTEIN A1; CLOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIPID METABOLISM; NONHUMAN; REVIEW; SINGLE DRUG DOSE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INTESTINES; LIPID METABOLISM; PHOSPHOLIPIDS;

EID: 40049086366     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Brook JG, Linn S, Aviram M: Dietary soya lecithin decreases plasma triglyceride levels and inhibits collagen- and ADP-induced platelet aggregation. Biochem Med Metab Biol (1986) 35(1):31-39.
2. Sirtori CR, Zucchi-Dentone C, Sirtori M, Gatti E, Descovich GC, Gaddi A, Cattin L, da Col PG, Senin U, Mannarino E: Cholesterol-lowering and HDL-raising properties of lecithinated soy proteins in type II hyperlipidemic patients. Ann Nutr Metab (1985) 29(6):348-357.
3. Childs MT, Bowlin JA, Ogilvie JT, Hazzard WR, Albers JJ: The contrasting effects of a dietary soya lecithin product and corn oil on lipoprotein lipids in normolipidemic and familial hypercholesterolemic subjects. Atherosclerosis (1981) 38(1-2):217-228.
4. Tompkins RK, Parkin LG: Effects of long-term ingestion of soya phospholipids on serum lipids in humans. Am J Surg (1980) 140(3):360-364. •• Significant reductions in serum cholesterol and triglycerides were reported in this clinical trial of large-dose soy lecithin.
5. Wilson TA, Meservey CM, Nicolosi RJ: Soy lecithin reduces plasma lipoprotein cholesterol and early atherogenesis in hypercholesterolemic monkeys and hamsters: Beyond linoleate. Atherosclerosis (1998) 140(1):147-153.
6. O'Brien BC, Corrigan SM: Influence of dietary soybean and egg lecithins on lipid responses in cholesterol-fed guinea pigs. Lipids (1988) 23(7):647-650.
7. Hunt CE, Duncan LA: Hyperlipoproteinemia and atherosclerosis in rabbits fed low-level cholesterol and lecithin. Br J Exp Pathology (1985) 66(1):35-46.
8. Lieber CS: New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep (2004) 6(1):60-65.
9. Stamler CJ. Breznan D, Neville TA, Viau FJ, Camlioglu E, Sparks DL: Phosphatidylinositol promotes cholesterol transport in vivo. J Lipid Res (2000) 41(8):1214-1221.
10. Burgess JW, Boucher J, Neville TA, Rouillard P, Stamler C, Zachariah S, Sparks DL: Phosphatidylinositol promotes cholesterol transport and excretion. J Lipid Res (2003) 44(7):1355-1363. •• Soy PI was shown to stimulate reverse cholesterol transport in New Zealand White rabbits. PI was also shown to act via cell surface ATP-binding cassette transporters and signaling pathways to regulate both cellular and intravascular cholesterol homeostasis.
11. Burgess JW, Neville TA, Rouillard P, Harder Z, Beanlands DS, Sparks DL: Phosphatidylinositol increases HDL-C levels in humans. J Lipid Res (2005) 46(2):350-355. •• This study provides evidence of the safety and HDL-elevating efficacy of soy phosphatidylinositol, when administered orally to normolipidemic individuals for 2 weeks.
12. Hopewell SJ, Malone K, Grimwood B, Sinclair P, Burgess J, Sparks DL: Phosphatidylinositol acts through mitogen and stress activated protein kinase pathways to stimulate secretion of apoA-I. Circulation (2006) 114(Suppl):18. •• This paper reports on how phosphatidylinositol impacts MAPK secretion of apoA-I from HepG2 cells without changes in apoA-I transcription.
13. Pandey NR, Renwick J, Misquith A, Sokoll K, Sparks DL: Linoleic acid-enriched phospholipids act on PPAR? to stimulate hepatic apoA-I synthesis and secretion. Biochemistry (2008) 47(6):1579-1587. •• This paper reports on the impact of phosphatidylinositol on MAPK and PPARα pathways to stimulate the secretion of apoA-I from HepG2 cells.
14. 2: Ether or acyl bond and polar head group selectivity. Biochim Biophys Acta (1987) 921(2):333-409.
15. Dawson RM, Hemington N, Irvine RF: The inhibition of diacylglycerol-stimulated intracellular phospholipases by phospholipids with a phosphocholine-containing polar group. A possible physiological role for sphingomyelin. Biochem J (1985) 230(1):61-68.
16. Asokan A, Cho MJ: Cytosolic delivery of macromolecules 4. Head group-dependent membrane permeabilization by pH-sensitive detergents. J Control Release (2005) 106(1-2):146-153.
17. Zeisel SH: Dietary choline: Biochemistry, physiology, and pharmacology. Ann Rev Nutr (1981) 1:95-121.
18. 2-deficient mice. Gastroenterology (2001) 120(5):1193-1202.
19. Coe NR, Smith AJ, Frohnert BI, Watkins PA, Bernlohr DA: The fatty acid transport protein (FATP1) is a very long chain acyl-CoA synthetase. J Biol Chem (1999) 274(51):36300-36304.
20. Stahl A, Hirsch DJ, Gimeno RE, Punreddy S, Ge P, Watson N, Patel S, Kotler M, Raimondi A, Tartaglia LA, Lodish HF: Identification of the major intestinal fatty acid transport protein. Mol Cell (1999) 4(3):299-308.
21. Schulthess G, Lipka G, Compassi S, Boffelli D, Weber FE, Paltauf F, Hauser H: Absorption of monoacylglycerols by small intestinal brush border membrane. Biochemistry (1994) 33(15):4500-4508.
22. Kosters A, Frijters RJ, Schaap FG, Vink E, Plösch T, Ottenhoff R, Jirsa M, De Cuyper IM, Kuipers F, Groen AK: Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol (2003) 38(6): 710-716. • This study demonstrated the role of ABCG5 and ABCG8 in the regulation of biliary cholesterol secretion in mice.
23. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs HH: Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest (2002) 110(5):671-680. • This study showed that the increased expression of ABCG5 and ABCG8 selectively drives biliary neutral sterol secretion and reduces intestinal cholesterol absorption in transgenic mice.
24. 50 values were high and suggested that soy lecithin extracts are safe.
25. Prueksaritanont T, Tang C, Oui Y, Mu L, Subramanian R, Lin RH: Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos (2002) 30(11):1280-1287. • This study investigated the metabolic interaction between fibrates (gemfibrozil) and statin hydroxy acids in human hepatocytes. The study showed that fibrates differ in their ability to affect the pharmacokinetics of statins.
26. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther (2002) 301(3):1042-1051.
27. Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, Byrne CB: Statin-fibrate combination: Therapy for hyperlipidemia: A review. Curr Med Res Opin (2003) 19(3): 155-168. •• This review provides an overview of major concerns and safety guidelines for the use of statin-fibrate combination therapy.
28. Shek A, Ferrill MJ: Statin-fibrate combination therapy. Ann Pharmacother (2001) 35(7-8):908-917.
29. Shepherd J: Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur Heart J (1995) 16(1):5-13.
30. Kannisto K, Chibalin A, Glinghammar B, Zierath JR, Hamsten A, Ehrenborg E: Differential expression of peroxisomal proliferator activated receptors ? and ? in skeletal muscle in response to changes in diet and exercise. Int J Mol Med (2006) 17(1):45-52. • Fibrate and exercise were used as combination therapy and were shown to be potentially effective in the management of metabolic syndrome.
31. Kim DK, Young JA, Park M: The effect of combination therapy with exercise and fenofibrate for the metabolic syndrome in rats. Am Meet Diabetes Assoc (2005) 65: Abs 1794.